Multi-Modality Echocardiographic Techniques in Pathological Left Ventricular Hypertrophy Adults
MET-LVH
Characteristics of the Multi-Modality Echocardiographic Techniques in Chinese Adults With Pathological Left Ventricular Hypertrophy - a Prospective, Multicenter, Clinical Study (MET-LVH Study)
1 other identifier
observational
660
1 country
22
Brief Summary
This multicenter clinical study aims to evaluate the multi-modality echocardiographic parameters in patients with different pathological left ventricular hypertrophy (LVH) and investigate the correlation between echocardiographic parameters and different etiologies, providing an important theoretical basis for early identification and risk assessment in LVH patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2023
Typical duration for all trials
22 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2023
CompletedFirst Submitted
Initial submission to the registry
January 29, 2023
CompletedFirst Posted
Study publicly available on registry
February 8, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 5, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 5, 2025
CompletedFebruary 10, 2023
February 1, 2023
1.6 years
January 29, 2023
February 8, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Conventional echocardiographic parameters in all pathological LVH patients
To evaluate the conventional two-dimensional, color Doppler, spectral Doppler and tissue Doppler echocardiographic parameters in all pathological LVH patients.
1 day after admission
Secondary Outcomes (2)
Strain parameters in all pathological LVH patients
1 day after admission
Volume and mass parameters in all pathological LVH patients
1 day after admission
Study Arms (4)
Hypertensive heart disease group
Systolic blood pressure exceeded 140 mmHg and/or diastolic blood pressure exceeded 90 mmHg, or a history of systemic hypertension in the absence of other cardiac or systemic disease was described as hypertension.
Hypertrophic cardiomyopathy group
Wall thickness≥15 mm in the absence of other causes of hypertrophy in a non-dilated left ventricle (LV) defines HCM. End diastolic wall thickness≥13 mm can be diagnostic if there is a family history of HCM or a known disease-causing genetic mutation.
Cardiac amyloidosis group
Clinical diagnosis of cardiac amyloidosis confirmed by blood tests or tissue biopsy.
Fabry disease group
Clinical diagnosis of Fabray disease confirmed by blood biomarkers or genetic testing.
Interventions
Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
Eligibility Criteria
Patients with left ventricular hypertrophy (LVH) detected by echocardiography.
You may qualify if:
- Age ≥ 18 years old;
- A wall thickness ≥ 12mm in one or more LV myocardial segments as measured by 2D echocardiography.
- Patients with definite diagnosis of hypertensive heart disease, hypertrophic cardiomyopathy, cardiac amyloidosis or Fabry disease.
You may not qualify if:
- Patients with severe valvular disease, congenital heart disease, aortic coarctation, multiple Takayasu arteritis, or other cardiovascular diseases that may cause ventricular hypertrophy;
- Hypertrophy of myocardium caused by high intensity exercise;
- Poor ultrasonic image quality, which cannot meet analysis requirement.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (22)
the Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
the First Affiliated Hospital of Jiamusi University
Jiamusi, Heilongjiang, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
the Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Ansteel Group General Hospita
Anshan, Liaoning, China
Benxi Central Hospital
Benxi, Liaoning, China
Chaoyang Central Hospital
Chaoyang, Liaoning, China
Dalian Municipal Central Hospital
Dalian, Liaoning, China
the Second Hospital of Dalian Medical University
Dalian, Liaoning, China
Dandong Central Hospital
Dandong, Liaoning, China
Fushun Central Hospital
Fushun, Liaoning, China
the First Affiliated Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China
Affiliated Central Hospital of Shenyang Medical College
Shenyang, Liaoning, China
Dadong Branch of First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
the First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Shenyang, Liaoning, China
the First Hospital of China Medical Univeristy
Shenyang, Liaoning, China
the Second Affiliated Hospital of Shenyang Medical College
Shenyang, Liaoning, China
Liao Jian Group Tie Mei General Hospital
Tieling, Liaoning, China
Tieling Central Hospital
Tieling, Liaoning, China
Tianjin Chest Hospital
Tianjin, Tianjin Municipality, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chunyan Ma, Ph.D
the First Hospital of China Medical Univeristy
- PRINCIPAL INVESTIGATOR
Li Zhang, Ph.D
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief of Cardiovascular Ultrasound
Study Record Dates
First Submitted
January 29, 2023
First Posted
February 8, 2023
Study Start
January 1, 2023
Primary Completion
August 5, 2024
Study Completion
August 5, 2025
Last Updated
February 10, 2023
Record last verified: 2023-02